Patients who received the first FDA-approved trifocal IOL reported high satisfaction with the lens, but some can experience some contrast or quality diminution even with final 20/20 vision, according to a speaker at the virtual American Society of Cataract and Refractive Surgery meeting.
“Some halos are present in 50% of patients, but most of these patients would still choose this lens again,” Sheri L. Rowen, MD, ABO, said.
Rowen and her colleague, Duna Raoof, MD, implanted the AcrySof IQ PanOptix trifocal IOL (Alcon) in patients first starting in September 2019 (Read more...)
Uncategorized